Symbols

FATE

Fate Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FATE

Fate Therapeutics, Inc.

A clinical-stage biopharmaceutical company that developing programmed cellular immunotherapies for the treatment of cancer diseases

Industry

Pharmaceutical

Established Date

04/27/2007

Listing Date

10/01/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

161

Fiscal Year Ends

12-31

Website

www.fatetherapeutics.com

Security Type

Common stock

Office address

12278 Scripps Summit Drive, San Diego, California 92131

Business

Introduction

Fate Therapeutics, Inc., was incorporated in Delaware on April 27, 2007 and is headquartered in San Diego, California. As a clinical-stage biopharmaceutical company, the company focuses on the development of off-the-shelf, multi-engineered, induced pluripotent stem cell (iPSC) -derived cellular immunotherapies for patient treatment.

Company Financials

EPS

FATE has released its 2025 Q4 earnings. EPS was reported at -0.27, versus the expected -0.27, meeting expectations. The chart below visualizes how FATE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FATE has released its 2025 Q4 earnings report, with revenue of 1.37M, reflecting a YoY change of -26.40%, and net profit of -32.37M, showing a YoY change of 37.92%. The Sankey diagram below clearly presents FATE's revenue sources and cost distribution.